Literature DB >> 25139358

Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.

Sudipto Ganguly1, Duncan B Ross2, Angela Panoskaltsis-Mortari3, Christopher G Kanakry1, Bruce R Blazar3, Robert B Levy2, Leo Luznik1.   

Abstract

Posttransplantation cyclophosphamide (PTCy) is an effective prophylaxis against graft-versus-host disease (GVHD). However, it is unknown whether PTCy works singularly by eliminating alloreactive T cells via DNA alkylation or also by restoring the conventional (Tcon)/regulatory (Treg) T-cell balance. We studied the role of Tregs in PTCy-mediated GVHD prophylaxis in murine models of allogeneic blood or marrow transplantation (alloBMT). In 2 distinct MHC-matched alloBMT models, infusing Treg-depleted allografts abrogated the GVHD-prophylactic activity of PTCy. Using allografts in which Foxp3(+) Tregs could be selectively depleted in vivo, either pre- or post-PTCy ablation of donor thymus-derived Tregs (tTregs) abolished PTCy protection against GVHD. PTCy treatment was associated with relative preservation of donor Tregs. Experiments using combinations of Foxp3(-) Tcons and Foxp3(+) Tregs sorted from different Foxp3 reporter mice indicated that donor Treg persistence after PTCy treatment was predominantly caused by survival of functional tTregs that retained Treg-specific demethylation and also induction of peripherally derived Tregs. Finally, adoptive transfer of tTregs retrieved from PTCy-treated chimeras rescued PTCy-treated, Treg-depleted recipients from lethal GVHD. Our findings indicate that PTCy-mediated protection against GVHD is not singularly dependent on depletion of donor alloreactive T cells but also requires rapidly recovering donor Tregs to initiate and maintain alloimmune regulation.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25139358      PMCID: PMC4186542          DOI: 10.1182/blood-2013-10-525873

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  52 in total

Review 1.  Tregs and transplantation tolerance.

Authors:  Patrick T Walsh; Devon K Taylor; Laurence A Turka
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

2.  Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer.

Authors:  G Schiavoni; F Mattei; T Di Pucchio; S M Santini; L Bracci; F Belardelli; E Proietti
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

3.  Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter.

Authors:  Yisong Y Wan; Richard A Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-28       Impact factor: 11.205

Review 4.  Cyclophosphamide-induced immunological tolerance: an overview.

Authors:  H Mayumi; M Umesue; K Nomoto
Journal:  Immunobiology       Date:  1996-07       Impact factor: 3.144

5.  Regulatory T cell lineage specification by the forkhead transcription factor foxp3.

Authors:  Jason D Fontenot; Jeffrey P Rasmussen; Luke M Williams; James L Dooley; Andrew G Farr; Alexander Y Rudensky
Journal:  Immunity       Date:  2005-03       Impact factor: 31.745

6.  Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.

Authors:  M E Christine Lutsiak; Roshanak T Semnani; Roberto De Pascalis; Syed V S Kashmiri; Jeffrey Schlom; Helen Sabzevari
Journal:  Blood       Date:  2004-12-09       Impact factor: 22.113

7.  Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice.

Authors:  Jeong M Kim; Jeffrey P Rasmussen; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2006-11-30       Impact factor: 25.606

8.  Prevention of graft versus host disease by inactivation of host antigen-presenting cells.

Authors:  W D Shlomchik; M S Couzens; C B Tang; J McNiff; M E Robert; J Liu; M J Shlomchik; S G Emerson
Journal:  Science       Date:  1999-07-16       Impact factor: 47.728

9.  Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells.

Authors:  Sven Brode; Tim Raine; Paola Zaccone; Anne Cooke
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

10.  Epigenetic control of the foxp3 locus in regulatory T cells.

Authors:  Stefan Floess; Jennifer Freyer; Christiane Siewert; Udo Baron; Sven Olek; Julia Polansky; Kerstin Schlawe; Hyun-Dong Chang; Tobias Bopp; Edgar Schmitt; Stefan Klein-Hessling; Edgar Serfling; Alf Hamann; Jochen Huehn
Journal:  PLoS Biol       Date:  2007-02       Impact factor: 8.029

View more
  80 in total

Review 1.  Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective.

Authors:  F Saraceni; N Shem-Tov; A Olivieri; A Nagler
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

2.  A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.

Authors:  Sarah Nikiforow; Haesook T Kim; Heather Daley; Carol Reynolds; Kyle Thomas Jones; Philippe Armand; Vincent T Ho; Edwin P Alyea; Corey S Cutler; Jerome Ritz; Joseph H Antin; Robert J Soiffer; John Koreth
Journal:  Haematologica       Date:  2016-06-27       Impact factor: 9.941

3.  Situational aldehyde dehydrogenase expression by regulatory T cells may explain the contextual duality of cyclophosphamide as both a pro-inflammatory and tolerogenic agent.

Authors:  Christopher G Kanakry; Sudipto Ganguly; Leo Luznik
Journal:  Oncoimmunology       Date:  2015-03-20       Impact factor: 8.110

Review 4.  Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy.

Authors:  Piyanuch Kongtim; Dean A Lee; Laurence J N Cooper; Partow Kebriaei; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-11       Impact factor: 5.742

5.  Azacitidine Mitigates Graft-versus-Host Disease via Differential Effects on the Proliferation of T Effectors and Natural Regulatory T Cells In Vivo.

Authors:  Matthew L Cooper; Jaebok Choi; Darja Karpova; Kiran Vij; Julie Ritchey; Mark A Schroeder; John F DiPersio
Journal:  J Immunol       Date:  2017-03-22       Impact factor: 5.422

Review 6.  Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation?

Authors:  F Lussana; M Di Ianni; A Rambaldi
Journal:  Bone Marrow Transplant       Date:  2017-03-20       Impact factor: 5.483

Review 7.  Cytokine mediators of chronic graft-versus-host disease.

Authors:  Kelli Pa MacDonald; Bruce R Blazar; Geoffrey R Hill
Journal:  J Clin Invest       Date:  2017-06-30       Impact factor: 14.808

8.  Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia.

Authors:  Greg D Whitehill; Shoba Amarnath; Pawel Muranski; Keyvan Keyvanfar; Minoo Battiwalla; Austin J Barrett; Dhanalakshmi Chinnassamy
Journal:  Mol Ther       Date:  2016-07-06       Impact factor: 11.454

9.  STING differentially regulates experimental GVHD mediated by CD8 versus CD4 T cell subsets.

Authors:  Cameron S Bader; Henry Barreras; Casey O Lightbourn; Sabrina N Copsel; Dietlinde Wolf; Jingjing Meng; Jeonghyun Ahn; Krishna V Komanduri; Bruce R Blazar; Lei Jin; Glen N Barber; Sabita Roy; Robert B Levy
Journal:  Sci Transl Med       Date:  2020-07-15       Impact factor: 17.956

10.  Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis.

Authors:  P V O'Donnell; M Eapen; M M Horowitz; B R Logan; A DiGilio; C Brunstein; E J Fuchs; M E D Flowers; R Salit; K Raj; A Pagliuca; K Bradstock; A Granata; L Castagna; S Furst; D Blaise
Journal:  Bone Marrow Transplant       Date:  2016-08-15       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.